Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS – Get Free Report) has earned a consensus recommendation of “Buy” from the seven research firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among analysts that have covered the stock in the last year is $54.20.
TARS has been the topic of several recent research reports. The Goldman Sachs Group raised their price target on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a report on Friday, November 15th. William Blair upgraded Tarsus Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th. Finally, Oppenheimer upped their price objective on Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the company an “outperform” rating in a report on Thursday, November 14th.
Read Our Latest Stock Report on TARS
Institutional Trading of Tarsus Pharmaceuticals
Tarsus Pharmaceuticals Trading Down 2.6 %
Shares of NASDAQ TARS opened at $50.32 on Friday. The company has a market cap of $1.92 billion, a price-to-earnings ratio of -13.21 and a beta of 1.04. Tarsus Pharmaceuticals has a 12-month low of $15.89 and a 12-month high of $52.99. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30. The stock’s 50 day simple moving average is $42.13 and its 200 day simple moving average is $33.63.
Tarsus Pharmaceuticals Company Profile
Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.
See Also
- Five stocks we like better than Tarsus Pharmaceuticals
- What Are Treasury Bonds?
- NVIDIA’s Blackwell Chips Set for Arizona Manufacturing by TSMC?
- How to Calculate Stock Profit
- Okta: Bullish Signals Suggest a Market Reversal Is Underway
- P/E Ratio Calculation: How to Assess Stocks
- BlackRock Makes Waves With $12B Private Credit Acquisition
Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.